Yestar Health (02393.HK) announced that the unaudited comprehensive net profit for the first six months of the group ending on June 30, 2023 was approximately 11.6 million yuan. The company expects that the unaudited comprehensive net profit during the mid-term period around 2024 will increase significantly by no less than 1,050 million yuan.

The expected significant growth in the group's mid-term net profit mainly stems from (i) the recognition of substantial premiums due to the redemption of preferred notes originally due in 2026 at a discount; and (ii) reduced financial costs after the redemption of relevant preferred notes.